Risk-Reducing Mastectomy and Survival in BRCA Carriers: What the New Data Say (Update)
In this article
Risk-Reducing Mastectomy and Survival in BRCA Carriers: What the New Data Say (Update)
A network meta-analysis published in JAMA Network Open on October 30, 2026 pooled five observational studies covering 7,937 women who carry a pathogenic variant in BRCA1 or BRCA2. Risk-reducing (preventive) mastectomy was associated with a lower overall loss of life from any cause than MRI-based surveillance. However, the certainty of the evidence is very low, and across the whole group an advantage over MRI for loss of life from breast cancer was not statistically established. “Everyone should have surgery” cannot be concluded from this. This article does not interpret anyone’s report or treatment: decisions about surgery and surveillance are made together with the physicians who follow you and with genetic counseling.
This article updates our earlier piece, Do risk-reducing surgeries lower the risk of loss of life in BRCA mutation carriers? (Türkçe), with new data. The earlier article discussed a study of carriers who had already been diagnosed with breast cancer at a young age; this new analysis looks at carriers who have not had breast or ovarian cancer. The two studies answer different questions.
- What was done? A network meta-analysis of five observational studies comparing risk-reducing mastectomy, MRI-based surveillance and mammography alone in women with BRCA1/2 variants. Studies that included women with prior breast or ovarian cancer were excluded.
- What was found? Risk-reducing mastectomy was associated with a lower risk of loss of life from any cause than MRI surveillance and than mammography. For loss of life from breast cancer there was a difference versus mammography; versus MRI, significance was not established.
- What remains unsettled? Causality, the advantage over MRI for loss of life from breast cancer in the whole group, and BRCA2-specific results.
- Level of evidence: Very low certainty; critical risk of bias in four studies and moderate in one. There is no randomized controlled trial.
What did this analysis do?
A network meta-analysis is a method that allows comparisons by combining, within one shared network, studies that did not compare the same groups directly. Here, risk-reducing mastectomy, MRI-based surveillance and mammography alone were compared for loss of life from any cause and from breast cancer. The authors also examined whether surgery has a contribution independent of risk-reducing removal of the ovaries and tubes (RRSO).
| Item | Detail |
|---|---|
| Design | Systematic review and frequentist random-effects network meta-analysis; registration: PROSPERO CRD420251141021 |
| Search | MEDLINE, Embase and Web of Science; January 1, 1990 to May 28, 2026; English-language observational studies |
| Included | Five observational studies, 7,937 women; median age 35.9–43.4, median follow-up 3.5–13.3 years |
| Population | Adult women with a pathogenic or likely pathogenic variant in BRCA1 or BRCA2; studies that included women with prior breast or ovarian cancer were excluded |
| Compared | Risk-reducing mastectomy, MRI-based surveillance and mammography alone |
| Outcomes | Primary: loss of life from any cause; secondary: loss of life from breast cancer |
| RRSO | Adjusted multivariably in most studies; excluded by design in one study |
Source: Beshar et al., JAMA Network Open, 2026;9(10):e2641231 (DOI 10.1001/jamanetworkopen.2026.41231). BRCA1 predominated in three cohorts; BRCA2-specific data were limited.
Figure 1 · Flow of the analysis
From five observational studies to certainty of evidence: four steps
What was found?
A hazard ratio below 1 means that in that comparison the risk of loss of life appears lower in the risk-reducing mastectomy group. For loss of life from any cause, risk-reducing mastectomy was associated with a lower risk than both MRI surveillance and mammography alone. For loss of life from breast cancer the difference versus mammography was clear; versus MRI the confidence interval includes 1, so the difference was not established.
| Outcome | Comparison (surgery versus) | Hazard ratio (95% CI) | Interpretation |
|---|---|---|---|
| From any cause | MRI surveillance | 0.37 (0.22–0.63) | Significant |
| From any cause | Mammography alone | 0.16 (0.08–0.32) | Significant; indirect comparison |
| From breast cancer | Mammography alone | 0.07 (0.01–0.44) | Significant; indirect comparison |
| From breast cancer | MRI surveillance | 0.26 (0.05–1.35) | Not established; interval includes 1 |
| From breast cancer, BRCA1 only | MRI surveillance / mammography alone | 0.13 (0.03–0.66) / 0.03 (0.00–0.15) | Significant in BRCA1 |
When single-center studies were removed, the hazard ratios for loss of life from any cause remained 0.42 (0.22–0.77) and 0.18 (0.08–0.39). E-values of 4.85 (point estimate) and 2.66 (confidence limit) were calculated; this measure shows how strong a hidden confounder would have to be to explain the observed association on its own.
Why was the evidence rated “very low certainty”?
The authors rated the certainty of evidence as very low for all comparisons. Of the five studies, the risk of bias was critical in four and moderate in one. In observational studies, women who choose surgery may differ from those who do not in age, general health and access to care; this difference can tilt the result in favor of surgery.
The authors point to two specific problems. First, residual confounding most likely favors the surgery group, so it may make the benefit look larger than it is. Second, “immortal time bias”: because those who have surgery must have survived until the operation, this bias can give the surgical group an advantage, and only some studies tried to correct for it. In addition, the comparison between surgery and mammography rests on indirect, not direct, evidence.
In conclusion, this analysis does not prove that surgery reduces loss of life; it shows that the association looks strong and consistent, but that its reliability is low.
Figure 2 · Steps of evidence
What can and cannot be concluded from these data?
How this relates to our earlier article
Our earlier article and this analysis are not meant to confirm or refute each other; they look at different groups of women and ask different questions.
| Earlier article | This analysis | |
|---|---|---|
| Who? | BRCA1/2 carriers diagnosed with breast cancer at a young age | BRCA1/2 carriers who have not had breast or ovarian cancer |
| Question | Survival in those who had risk-reducing surgery | Loss of life with risk-reducing mastectomy, MRI surveillance and mammography |
| Method | Retrospective international cohort | Network meta-analysis of five observational studies |
Both rest on observational designs; in both, the decision to have surgery depends on the patient and the care team, so selection bias is likely.
Common misunderstandings
- “Every BRCA carrier should have surgery.” No. The analysis reports a low-certainty association, not a recommendation; even the authors stress individualized counseling.
- “Surgery definitely extends life.” No. The risk of bias in the observational data is critical; causality was not shown.
- “MRI surveillance is inadequate.” No. For loss of life from breast cancer, the advantage of surgery over MRI was not established across the whole group.
- “The result is the same for BRCA2.” No. BRCA2-specific data were limited; the clear result for loss of life from breast cancer was seen in the BRCA1-specific analyses.
What does this news mean for you?
- This analysis does not make the decision about preventive surgery for you; age, family history, plans for having children and personal preference are all part of that decision.
- Make the decision together with a team that includes genetic counseling, breast surgery, oncology and, where needed, psychological support.
- Removal of the ovaries and tubes is a separate decision; this analysis tried to adjust for it as a separate variable, but the adjustment was not the same in all studies.
For this article we did not check access to BRCA testing and preventive surgery in Türkiye, nor licensing, reimbursement or center practices; we did not make assumptions on these points. For broader information, see our articles on the preventive surgery strategy (Türkçe) and on how preventable breast cancer is (Türkçe).
DROZDOGAN Academy Assessment
This analysis is a carefully reported network meta-analysis that addresses risk-reducing mastectomy in BRCA carriers with a less confounded method. However, its input is observational data; its results are not a strong basis for an individual decision, but data to be weighed in counseling.
⚡ Why it matters
The choice between risk-reducing mastectomy and MRI surveillance is a heavy decision for carriers, and a randomized controlled trial is not expected. Investigating the contribution independent of ovarian surgery and comparing surveillance methods separately is a practical question for counseling.
✅ What is strong
A registered protocol, PRISMA-compliant reporting, explicit assessment of bias and certainty of evidence, a sensitivity analysis with single-center studies removed, and E-values. The authors also state their limitations openly.
⚠️ What is weak
Only five observational studies, four with critical risk of bias. Certainty of evidence is very low. The comparison between surgery and mammography is indirect. BRCA2-specific data are limited; subgroup interactions by age or variant could not be tested. We did not look at patient-level data or the supplementary material.
🩺 Practical meaning for patient and physician
In counseling, the data reporting lower loss of life associated with risk-reducing mastectomy can be presented as “information to be weighed”; but it should be said together with its low certainty and the fact that MRI surveillance has not been shown to fall behind for loss of life from breast cancer.
❓ Open questions
Will prospective data with less bias confirm this association? What is the result in BRCA2 carriers? Do age and family history change the result? This analysis answers none of these questions.
Bottom line: In low-certainty observational data, risk-reducing mastectomy was associated with lower loss of life from any cause; this is not a basis for recommending surgery to everyone. No diagnostic or treatment decision should be made on the basis of this finding; discuss everything about your own situation with the physician who follows you.
Frequently asked questions
- What did this analysis show?
- In women carrying BRCA1/2, risk-reducing mastectomy was associated with lower loss of life from any cause than MRI surveillance and mammography alone. The certainty of the evidence is very low.
- Should everyone have surgery?
- No. No such conclusion can be drawn from the analysis; the decision is individual and made through counseling.
- Is MRI surveillance as good as surgery?
- Unknown. For loss of life from breast cancer, the advantage of surgery over MRI was not established across the whole group; it was significant in BRCA1-specific analyses.
- Does it apply to BRCA2 carriers as well?
- Uncertain. BRCA2-specific data were limited.
- Does this contradict your earlier article?
- No. The earlier article looked at a study of young carriers who had been diagnosed with cancer; this analysis examines carriers who have not had cancer. The two answer different questions.
Glossary
- Risk-reducing (preventive) mastectomy
- Surgical removal of breasts without cancer in order to reduce breast cancer risk.
- RRSO
- Risk-reducing salpingo-oophorectomy: surgical removal of the ovaries and fallopian tubes.
- Network meta-analysis
- A statistical method that compares options that were not directly compared by combining them in one shared network.
- Hazard ratio (HR)
- A ratio comparing the rate of an event in two groups; below 1 means a lower rate.
- GRADE
- A system that grades certainty of evidence as high, moderate, low or very low.
- Immortal time bias
- A bias that favors the intervention group because those who receive an intervention must have survived until they received it.
- E-value
- A measure of how strong a hidden confounder would have to be to explain the observed association on its own.
- MRI-based surveillance
- A breast cancer surveillance program that includes regular magnetic resonance imaging.
Verified: The abstract, key points, results and limitations were taken from the article’s open-access page and compared across two separate readings; the numbers match the summary you sent. Our earlier article on the site was also read. Stated only: We did not read the patient-level results of the individual included studies, the supplementary materials or the peer-review reports; we reached the page content through an automatic summarization tool, so we did not write study-level details (for example, the number of patients in each study). Not verified, and therefore not written: subgroup results by age, variant type or family history; the access and reimbursement situation in Türkiye; overlap with other articles on drozdogan.com (only two articles were read; the whole site was not checked). Assessments and opinions belong to this article. This article is not medical advice; no diagnosis should be made and no treatment decision taken on its basis.
Who is this article for? BRCA carriers, their relatives and healthcare professionals. Only the physicians who follow you can make decisions about your own situation.
References
- Beshar I, Viveros-Carreño D, Agusti N, et al. Survival After Risk-Reducing Mastectomy in Patients With Pathogenic Variants in BRCA1 and BRCA2: A Network Meta-Analysis. JAMA Network Open, 2026;9(10):e2641231. DOI 10.1001/jamanetworkopen.2026.41231. doi.org
Was this article helpful?
Your feedback helps us improve our content.
